Shonali Midha, MD

Articles by Shonali Midha, MD

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

ByShonali Midha, MD

September 29th 2023

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.

Irene Ghobrial, MD, of Dana-Farber Cancer Institute

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

ByShonali Midha, MD,Omar Nadeem, MD,Irene Ghobrial, MD

March 29th 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

Shonali Midha, MD

Articles by Shonali Midha, MD

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

Latest Updated Articles

Trending on OncLive

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL